Why Adicet Bio, Inc.’s (ACET) Stock Is Down 6.42%
As of Friday, October 16, Adicet Bio, Inc.’s ACET share price has dipped by 6.42%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 5.97%
As of Tuesday, October 13, Adicet Bio, Inc.’s ACET share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 6.15%
As of Thursday, October 08, Adicet Bio, Inc.’s ACET share price has dipped by 6.15%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.12%
As of Wednesday, September 30, Adicet Bio, Inc.’s ACET share price has surged by 5.12%, which has investors questioning if this is right time to sell.Michael Rose
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.35%
As of Tuesday, September 29, Adicet Bio, Inc.’s ACET share price has surged by 5.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ACET | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $32.8 | $219.9 | 14% |
|
| Shares Out (Mil) | 10.7 | 54.1 | 22% |
|
| Institutional Ownership | 92.5% | 92.9% | 61% |
|
| Float (Mil) | 7.2 | 41.4 | 16% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 233 | 522 | 46% |
|
| Price Change (52-week) |
(72.4%) | 44.7% | 11% |
|
| Growth | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (26.1%) | (10.1%) | 16% |
|
| EPS (5yr) | 26.7% | 15.8% | 78 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.7%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($1.578) | ($6.358) | ($4.040) | |
| Month Ago EPS | ($1.578) | ($6.358) | ($4.040) | |
| # Rev Up | 2 | 2 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($1.538) | ($5.983) | ($3.020) | |
| Year/Year Chg | (10.3%) | (62.5%) | (95.0%) | |
| Financials | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($91) | ($44) | 12% |
|
| EPS (TTM) | ($8.527) | ($1.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($80) | ($35) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $0 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | ($57) | $166 | 1% |
|
| Valuation | ACET | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.28 | 2.06 | 6% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ACET | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (67.5%) | (47.5%) | 9% |
|
| ROE | (85.9%) | (52.7%) | 10% |
|
| Liabilities to Assets | 20.4% | 29.6% | 13% |
|
| F-Score | 2 | 3 | 7% |
|
Adicet Bio, Inc. did not pass any screens on 11/6/2026.
